Aurinia Q2 revenue up 47% to $41.5M; raises FY 2023 guidance to $150-160M

Aurinia Pharmaceuticals Inc.

2023-Q2 EPS reported -$0.26 revenue$75,903,000

Q2 net revenue $41.5M (+47% YoY); net loss narrowed to $11.5M ($0.08 loss per share) from $35.5M ($0.25).
Raised FY2023 LUPKYNIS revenue guidance to $150-160M; cited strong commercial execution.
Patients on therapy reached 1,911 (+50% YoY); patient start forms +10% YoY to 451 in Q2.
Gross margin 96%; cash and short-term investments $350.7M as of June 30, 2023.
Initiated strategic review with J.P. Morgan as financial advisor.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aurinia Pharmaceuticals Inc. reported three and six months ended June 30, 2023 results: revenue $41.5 million. Guidance raised.

Period: three and six months ended June 30, 2023
Revenue: $41.5 million
Guidance: raised
Result: reported results

Exact text from the filing

Total net revenue was $41.5 million for the three months ended June 30, 2023

View on SEC.gov

35 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.